Literature DB >> 10454455

Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.

N J Brown1, M Agirbasli, D E Vaughan.   

Abstract

Angiotensin-converting enzyme (ACE) inhibition significantly decreases plasminogen activator inhibitor-1 (PAI-1) without altering tissue plasminogen activator (tPA) during activation of the renin-angiotensin-aldosterone system in humans. Because ACE inhibitors and angiotensin II type 1 (AT(1)) receptor antagonists differ in their effects on angiotensin II formation and bradykinin degradation, the present study compared the effect of equivalent hypotensive doses of an ACE inhibitor and AT(1) antagonist on fibrinolytic balance. Plasma PAI-1 antigen, tPA antigen, plasma renin activity, and aldosterone were measured in 25 normotensive subjects (19 white, 6 black; 14 men, 11 women; mean age 38.5+/-1.8 years; mean body mass index 25.3+/-0.7 kg/m(2)) during low salt intake alone (10 mmol Na/d), low salt intake + quinapril (40 mg PO bid), and low salt intake + losartan (50 mg PO bid). Compared with low salt alone (systolic blood pressure [BP] 118.8+/-2.2 mm Hg), both quinapril (106.3+/-2.5 mm Hg, P<0.001) and losartan (105.4+/-2. 8 mm Hg, P<0.001) reduced BP. No statistical difference was found between quinapril and losartan in their BP lowering effect. Losartan (P=0.009), but not quinapril, lowered heart rate. Both drugs significantly lowered aldosterone (P<0.001 versus low salt alone for each); however, this effect was significantly greater for quinapril than for losartan (P<0.001 for quinapril versus losartan). Treatment with quinapril, but not with losartan, was associated with a decrease in both PAI-1 antigen (P=0.03) and activity (P=0.018). PAI-1 activity was lower during treatment with quinapril than with losartan (P=0.015). The average PAI-1 antigen concentration was 13. 0+/-2.0 ng/mL during low salt alone, 10.5+/-1.6 ng/mL during quinapril treatment, and 12.3+/-2.1 ng/mL during losartan treatment. In contrast, plasma tPA antigen concentrations were reduced during treatment with losartan (P=0.03) but not with quinapril. This study provides the first evidence that ACE inhibitors and AT(1) antagonists differ in their effects on fibrinolytic balance under conditions of activation of the renin-angiotensin-aldosterone system. Further studies are needed to address the mechanism for the contrasting effects of these 2 classes of drugs on fibrinolysis and to define the clinical significance of these differences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454455     DOI: 10.1161/01.hyp.34.2.285

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.

Authors:  Folkert W Asselbergs; Scott M Williams; Patricia R Hebert; Christopher S Coffey; Hans L Hillege; Gerjan Navis; Douglas E Vaughan; Wiek H van Gilst; Jason H Moore
Journal:  Genomics       Date:  2007-01-05       Impact factor: 5.736

Review 2.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

3.  Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.

Authors:  Ken Yajima; Akira Shimada; Hiroshi Hirose; Yoichi Oikawa; Satoru Yamada; Shu Meguro; Junichiro Irie; Seiko Irie
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker.

Authors:  Ken Ishibashi; Satoshi Kurisu; Yasuko Kato; Naoya Mitsuba; Yoshihiro Dohi; Kenji Nishioka; Yasuki Kihara
Journal:  Heart Vessels       Date:  2011-11-02       Impact factor: 2.037

Review 5.  Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?

Authors:  S P Glasser
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

6.  Gender-specific genetic associations of polymorphisms in ACE, AKR1C2, FTO and MMP2 with weight gain over a 10-year period.

Authors:  Freek G Bouwman; Jolanda M A Boer; Sandra Imholz; Ping Wang; W M Monique Verschuren; Martijn E T Dollé; Edwin C M Mariman
Journal:  Genes Nutr       Date:  2014-10-17       Impact factor: 5.523

7.  Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems.

Authors:  John P Bentley; Folkert W Asselbergs; Christopher S Coffey; Patricia R Hebert; Jason H Moore; Hans L Hillege; Wiek H van Gilst
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

8.  Enhanced fibrinolysis protects against lung ischemia-reperfusion injury.

Authors:  Christine L Lau; Yunge Zhao; Jiyoun Kim; Irving L Kron; Ashish Sharma; Zequan Yang; Victor E Laubach; Joel Linden; Gorav Ailawadi; David J Pinsky
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05       Impact factor: 5.209

9.  Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension.

Authors:  Salvatore Paterna; Vincenzo Di Garbo; Gino Avellone; Pietro Di Pasquale; Antonina Cacia; Antonio Tuttolomondo; Giuseppe Follone; Antonietta Cardinale; Tiziana Maniscalchi; Giuseppe Licata
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.

Authors:  Michael M Hirschl; Andreas Bur; Christian Woisetschlaeger; Ulla Derhaschnig; Anton N Laggner
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.